Eating disorders in people with phenylketonuria

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the prevalence of eating disorders and body weight concerns in adults and/or children with phenylketonuria (PKU) who are managed at Nancy University Hospital. It aims to describe how restrictive PKU diets and the underlying disease may relate to weight gain and disordered eating patterns. No interventions are described; data are collected on current practice and patient characteristics to identify gaps in detection and care. The study will help clinicians understand the potential need for routine screening for eating disorders in PKU patients. Country-specific practice and single-center scope are noted in the setup.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects followed for PKU at Nancy University Hospital
* Subjects willing to participate

Exclusion Criteria:

* Subjects not villing to participate

Where it's running

• CHRU de Nancy
  Nancy, France Recruiting

Study contacts

• Study coordinator: Eva Feigerlova, MD PhD MMEd
• Email: e.feigerlova@chru-nancy.fr
• Phone: +330383154796

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Impact of a Phenylalanine-Restricted Diet on Gut Health in Children with PKU

  This study looks at how a Phe-restricted diet, with or without sapropterin or sepiapterin, might affect gut health in kids with PKU.

  Recruiting Birmingham Women's and Children's NHS Foundation Trust · Birmingham · NCT07728032

• How Repinatrabit is processed in adults with liver or kidney impairment versus normal function

  This study tests how Repinatrabit is handled by the body in adults with moderate liver impairment or severe kidney impairment compared to adults with normal liver function.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Miami, Florida · NCT07713758

• GenSci144 tablets early-dose study for phenylketonuria treatment

  This early-phase trial tests a single dose of GenSci144 tablets in healthy adults to see if it is safe and tolerable, while also looking at how the body processes the drug.

  Recruiting Phase 1 Changchun GeneScience Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07685210

• Immune Modulation During Palynziq Treatment in Adults

  This study tests whether adding low-dose methotrexate can help people with PKU tolerate Palynziq better and achieve better blood levels of phenylalanine.

  Recruiting at 10 sites Phase 4 BioMarin Pharmaceutical · Los Angeles, California and 11 other locations · NCT07477691

• AG-181 safety and tolerability in people with phenylketonuria

  This trial will test AG-181 for safety and tolerability in people with PKU who have high blood phenylalanine and at least one R408W PAH mutation.

  Recruiting at 5 sites Phase 1 Agios Pharmaceuticals, Inc. · Indianapolis, Indiana and 4 other locations · NCT07241234

• JNT-517 treatment for adults with phenylketonuria (PKU)

  This study will test whether taking JNT-517 pills twice daily lowers high blood phenylalanine and is safe for adults with PKU.

  Recruiting at 26 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Los Angeles, California and 25 other locations · NCT06971731

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.